

SARC Semi-annual Meeting Agenda

8:00	Introduction	
	Welcome	
8:10	Chawla/Rosenfeld Developmental Therapeutics Symposium	
	Introduction	David Kirsch/ Bob Maki
	Lessons from Melanoma Immunotherapy	Bastian Schilling
	Immune Biology of Sarcoma and Immunotherapy	Daniel Speiser
	Anti-PD1 in Sarcoma: Clinical Approach	Hussein Tawbi
	<i>Discussion/Q&A</i>	Symposium Faculty
9:45	SARC Career Development	
	Career Development 2015 Program	R. Gorlick & L. Helman
	Identifying Novel Therapies in Pediatric RMS using high throughput screening for inhibitors of the PAX3-FOXO1 Oncogenic Transcription Factor	J. Shern
	<i>Discussion/Q&A</i>	R. Gorlick & L. Helman
10:15	Break	
10:30	SARC Clinical Trials	
	Clinical Trials Update	S. Okuno
	SARC012: Phase 2 trial of saracatinib in resected recurrent osteosarcoma	M. Merchant
	SARC016: Phase 2 trial of bevacizumab & everolimus in unresectable or metastatic MPNST	L. Helman
	SARC023: Phase 2 trial of ganetespib & sirolimus in unresectable or metastatic MPNST	L. Helman
	SARC021: Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic STS	W. Tap
	Pathology Central Review	A Lazar
	SARC024: Phase 2 trial of regorafenib in refractory lipo, osteo and Ewing/Ewing-like sarcomas	L. Davis
	SARC025/ESP1/SPORE 3: Phase 1 trial of niraparib and temozolomide in incurable Ewing sarcoma	S. Strauss
	SARC028: A Phase 2 Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas	H. Tawbi
	SPORE TRIAL: SARC018/SPORE 2: A Phase 2 Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse Following Prior Treatment with Gemcitabine-Containing Therapy	E. Choy
11:45	SARC Sarcoma SPORE	
	Update SARC Sarcoma SPORE Project	R. Pollock
	Closing Remarks	